

## List of Publications Nov 12, 2021

Prof. Tarja Saaresranta

Impact factors according to the list of 2020

### 1) Original articles in international peer-reviewed journals

1. Hirvonen E, Karlsson A, Saaresranta T, Laitinen T. Documentation of the patient's smoking status in common chronic diseases - analysis of medical narrative reports using the ULMFiT based text classification. *Eur Clin Respir J* 2021, accepted for publication
2. Bonsignore MR, Pepin JL, Cibella F, Barbera CD, Marrone O, Verbraecken J, Saaresranta T, Basoglu O, Trakada G, McNicholas WT, Bailly S, Pataka A, Kvamme JA, Hein H, Mihaicuta S, Grote L, Fanfulla F, on behalf of the ESADA Study Group. Excessive daytime sleepiness in obstructive sleep apnea (OSA) patients treated with continuous positive airway pressure (CPAP): data from the European Sleep Apnea Database (ESADA). *Front Neurol.* 2021 Aug 9;12:690008. doi: 10.3389/fneur.2021.690008. (IF 4.003)
3. Chung F, Waseem R, Pham C, Penzel T, Fang H, Bjorvatn B, Morin CM, Holzinger H, Espie CA, Benedict C, Cedernaes J, Saaresranta T, Kwok Wing YK, Nadorff MR, Dauvilliers Y, De Gennaro L, Plazzi G, Merikanto I, Matsui M, Leger L, Sieminski M, Partinen M for the International COVID Sleep Study (ICOSS) group. The association between high risk of sleep apnea, comorbidities, and risk of COVID-19: A population based international harmonized study. *Sleep Breath* 2021; 25:849-60. doi: 10.1007/s11325-021-02373-5. (IF 2.816)
4. Tasbakan MS, Grote L, Hedner J, Kvamme J-A, Verbraecken J, McNicholas WT, Roisman G, Tkacova R, Bonsignore MR, Saaresranta T, Steiropoulos P, Basoglu OK. Positive airway pressure (PAP) treatment reduces glycated hemoglobin (HbA1c) levels in obstructive sleep apnea patients with concomitant weight loss: Longitudinal data from the ESADA. *J Sleep Res* 2021; accepted for publication (IF 3.981)
5. Aro MM, Anttalainen U, Polo O, Saaresranta T. Mood, sleepiness, life-style and weight gain in sleep apnoea patients. *Eur Clin Respir J* 2021; Feb 17;8(1):1888394. doi: 10.1080/20018525.2021.1888394.
6. Staats R, Bailly S, Bonsignore MS, Ryan S, Riha RL, Schiza S, Verbraecken J, Basoglu OK, Saaresranta T, Pataka A, Ludka O, Lombardi C, Hedner J, Grote L. Impact of temperature on obstructive sleep apnoea in three different climate zones of Europe – data from the European Sleep Apnoea Database (ESADA). *J Sleep Res* 2021; Feb 17;8(1):1888394. doi: 10.1080/20018525.2021.1888394. (IF 3.981)
7. Kalleinen N, Aittokallio J, Lampio L, Kaisti M, Polo-Kantola P, Polo O, Heinonen OJ, Saaresranta T. Sleep during menopausal transition: A 10-year follow-up. *Sleep* 2021; Jun 1;44(6):zsaa283. doi: 10.1093/sleep/zsaa283. (IF 5.849)
8. Riha RL, Kotoulas SC, Pataka A, Kvamme JA, Joppa P, Hedner J; ESADA collaborators. Obstructive sleep apnoea in adult patients post-tonsillectomy. *Sleep Med.* 2021 78:189-192. doi: 10.1016/j.sleep.2020.11.024. (IF 3.492)
9. Feuth T, Saaresranta T, Karlsson A, Valtonen M, Peltola V, Rintala E, Oksi J. Is sleep apnea a risk factor for Covid-19? Findings from a retrospective cohort study. *Sleep Med Dis Int J.* 2020;4(3):61–65. DOI: 10.15406/smdij.2020.04.00075
10. Pépin JL, Georgiev O, Tiholov R, Attali V, Verbraecken J, Buyse B, Partinen M, Fietze I, Belev G, Dokic D, Tamisier R, Lévy P, Lecomte I, Lecomte JM, Schwartz JC, Dauvilliers Y; HAROSA I Study Group. Pitolisant for Residual Excessive Daytime Sleepiness in OSA Patients Adhering to CPAP: A Randomized Trial. *Chest.* 2020 Oct 26:S0012-3692(20)35105-9. doi: 10.1016/j.chest.2020.09.281. Online ahead of print. (IF 9.410)
11. Aro M, Saaresranta T, Vahlberg T, Anttalainen U. Medication of comorbidities in females with sleep-disordered breathing during long-term CPAP therapy. *Respir Med* 2020; Aug;169:106014. doi: 10.1016/j.rmed.2020.106014. Epub 2020 May 12. (IF 3.415)

12. Grote L, McNicholas WT, Hedner J; ESADA collaborators. Sleep apnoea management in Europe during the COVID-19 pandemic: data from the European Sleep Apnoea Database (ESADA). *Eur Respir J*. 2020 Jun 18;55(6):2001323. doi: 10.1183/13993003.01323-2020. Print 2020 Jun. (IF 16.671)
13. Myllylä M, Anttalainen U, Saaresranta T, Laitinen T. Motor vehicle accidents in CPAP compliant obstructive sleep apnea patients – a long-term observational study. *Sleep Breath* 2020; 24(3):1089-1095. doi: 10.1007/s11325-020-02023-2. (IF 2.816)
14. Myllylä M, Hammis A, Stepanov M, Anttalainen U, Saaresranta T, Laitinen T. Response to letter entitled "COPD-and-smoking-induced 'down regulation' of CO<sub>2</sub>-related vasoconstriction in the brain during CPAP for sleep apnea may paradoxically reduce risk of cardiovascular events. *Sleep Breath* 2020; 24(3):1183-1185. doi: 10.1007/s11325-020-02028-x. (IF 2.816)
15. Dauvilliers Y, Verbraecken J, Partinen M, Hedner J, Saaresranta T, Georgiev O, Tiholov R, Lecomte I, Tamisier R, Lévy P, Scart-Gres C, Lecomte JM, Schwartz JC, Pépin JL; HAROSA II study group. Pitolisant for daytime sleepiness in obstructive sleep apnea patients refusing CPAP: A randomized trial. *Am J Respir Crit Care Med*. 2020 May 1;201(9):1135-1145. doi: 10.1164/rccm.201907-1284OC. (IF 21.405)
16. Ettala OO, Saaresranta T, Syvänen KT, Kaipia AJ, Vahlberg TJ, Aarnio PT, Boström PJ, Korhonen PE. Decreased forced expiratory volume in first second is associated with erectile dysfunction in apparently healthy men. A preliminary study. *Int J Impot Res* 2020; 32:420-425. (IF 2.896)
17. Huhtakangas JK, Huhtakangas J, Bloigu R, Saaresranta T. Unattended sleep study in screening for sleep apnea in the acute phase of ischemic stroke. *Sleep Med* 2020; 65:121-126. (IF 3.492)
18. Huhtakangas JK, Saaresranta T, Bode MK, Bloigu R, Huhtakangas J. Stroke volume predicts nocturnal hypoxemia in the acute ischemic stroke after intravenous thrombolysis. *J Stroke Cerebrovasc Dis* 2019; 28:2481-7 (IF 2.136)
19. Aro M, Anttalainen U, Kurki S, Ijala K, Polo O, Saaresranta T. Gender-specific increase in leptin concentrations during long-term CPAP therapy. *Sleep Breath* 2020; 24:191-199. (IF 2.816)
20. Myllylä M, Hammis A, Stepanov M, Anttalainen U, Saaresranta T, Laitinen T. Response to letter entitled "CPAP adherence and cardiovascular disease: Beware of the healthy adherer effect". *Sleep Breath* 2020 Jun;24(2):601-602. doi: 10.1007/s11325-019-01850-2. Epub 2019 Apr 27. (IF 2.816)
21. Myllylä M, Hammis A, Stepanov M, Anttalainen U, Saaresranta T, Laitinen T. Nonfatal and fatal cardiovascular disease events in CPAP compliant obstructive sleep apnea patients. *Sleep Breath* 2019; 23:1209-1217 (IF 2.816)
22. Marrone O, Cibella F, Pépin JL, Grote L, Verbraecken J, Saaresranta T, Kvamme JA, Basoglu OK, Lombardi C, McNicholas WT, Hedner J, Bonsignore MR. Comment to the Editorial by KS Park and EW Kang "Is only fixed positive airway pressure a robust tool for kidney protection in patients with obstructive sleep apnea?" *J Thorac Dis* 2019;11(Suppl 3):S480-S482 (IF 2.895)
23. Tuominen J, Peltola K, Saaresranta T, Valli K. Sleep parameter assessment accuracy of a consumer home sleep monitoring ballistocardiograph Beddit Sleep Tracker: A validation study. *J Clin Sleep Med* 2019; 15:483-7. (IF 4.062)
24. Gunduz C, Kacmaz Basoglu O, Hedner J, Bonsignore MR, Hein H, Staats R, Bouloukaki I, Roisman G, Pataka A, Sliwinski P, Ludka O, Pepin JL, Grote L; European Sleep Apnoea Database collaborators. Hyperlipidaemia prevalence and cholesterol control in obstructive sleep apnoea: Data from the European sleep apnea database (ESADA). *J Intern Med*. 2019; 286:676-88. doi: 10.1111/joim.12952. (IF 8.989)
25. Pataka A, Bonsignore MR, Ryan S, Riha RL, Pepin JL, Schiza S, Basoglu OK, Sliwinski P, Ludka O, Steiropoulos P, Anttalainen U, McNicholas WT, Hedner J, Grote L; ESADA study group. Cancer prevalence is increased in females with sleep apnoea: data from the ESADA study. *Eur Respir J*. 2019 Jun 20;53(6). pii: 1900091. doi: 10.1183/13993003.00091-2019. Print 2019 Jun (IF 16.671)
26. Strollo PJ Jr, Hedner J, Collop N, Lorch DG Jr, Chen D, Carter LP, Lu Y, Lee L, Black J, Pépin JL, Redline S; Tones 4 Study Investigators. Solriamfetol for the Treatment of Excessive

- Sleepiness in OSA: A Placebo-Controlled Randomized Withdrawal Study. *Chest* 2019 155:364-374. (IF 9.410)
27. Huhtakangas JK, Saaresranta T, Bloigu R, Huhtakangas J. The evolution of sleep apnea during six months after acute ischemic stroke and thrombolysis. *J Clin Sleep Med* 2018; 14:2005-2011 (IF 4.062)
  28. Anttalainen U, Grote L, Fietze I, Riha RL, Ryan S, Staats R, Hedner J, Saaresranta T. Insomnia symptoms combined with nocturnal hypoxia associate with cardiovascular comorbidity in the European sleep apnea cohort (ESADA). *Sleep Breath* 2019; 23:805-14 (IF 2.816)
  29. Dieltjens M, Verbraecken JA, Hedner J, Vanderveken OM, Steiropoulos P, Kvamme JA, Saaresranta T, Tkacova R, Marrone O, Dogas Z, Schiza S, Grote L on behalf of the ESADA network. Use of the Clinical Global Impression scale in sleep apnea patients - Results from the ESADA database. *Sleep Med* 2019; 59:56-65. (IF 3.492)
  30. Bonsignore MR, Pepin JL, Anttalainen U, Schiza SE, Basoglu OK, Pataka A, Steiropoulos P, Dogas Z, Grote L, Hedner J, McNicholas WT, Marrone O; ESADA Study Group. Clinical presentation of patients with suspected obstructive sleep apnea and self-reported physician-diagnosed asthma in the ESADA cohort. *J Sleep Res* 2018; Dec;27(6):e12729. doi: 10.1111/jsr.12729. (IF 3.981)
  31. Gündüz C, Basoglu OK, Hedner J, Zou D, Bonsignore MR, Hein H, Staats R, Pataka A, Barbe F, Sliwinski P, Kent BD, Pepin JL, Grote L; European Sleep Apnea Database Collaborators. Obstructive sleep apnoea independently predicts lipid levels: Data from the European Sleep Apnea Database. *Respirology* 2018; Dec;23(12):1180-1189. doi: 10.1111/resp.13372. (IF 6.424)
  32. Marrone O, Cibella F, Pépin J-L, Grote L, Verbraecken J, Saaresranta T, Kvamme JA, Başoğlu OK, Lombardi C, McNicholas WT, Hedner J, Bonsignore MR; on behalf of the ESADA network. Fixed, but not autoadjusting CPAP attenuates the-time dependent decline in glomerular filtration rate in patients with obstructive sleep apnea. *Chest* 2018; 154:326-34. (IF 9.410)
  33. Basoglu OK, Zou D, Tasbakan MS, Hedner J, Ryan S, Verbraecken J, Escourrou P, Anttalainen U, Kvamme JA, Bonsignore MR, Schiza S, Grote L; ESADA Study Group. Change in weight and central obesity by positive airway pressure treatment in obstructive sleep apnea patients: longitudinal data from the ESADA cohort. *J Sleep Res.* 2018 Dec;27(6):e12705. doi: 10.1111/jsr.12705. (IF 3.981)
  34. Huhtakangas J, Huhtakangas J, Bloigu R, Saaresranta T. Prevalence of sleep apnea at the acute phase of ischemic stroke with or without thrombolysis. *Sleep Med* 2017; 40:40-46. (IF 3.492)
  35. Lampio L, Polo-Kantola P, Kurki S, Himanen S-L, Engblom J, Heinonen O, Polo O, Saaresranta T. Sleep during menopausal transition: A six-year follow-up. *Sleep* 2017; 40:71 July 2017, zsx089, <https://doi.org/10.1093/sleep/zsx089> (IF 5.849)
  36. Lampio L, Saaresranta T, Engblom J, Polo O, Polo-Kantola P. Predictors for sleep disturbances in menopausal transition. *Maturitas* 2016; 94:137-42. (IF 2.953)
  37. Saaresranta T, Hedner J, Bonsignore MR, Riha RL, McNicholas WT, Pentzel T, Anttalainen U, Kvamme JA, Pretl M, Sliwinski P, Verbraecken J, Grote L. Clinical phenotypes and comorbidity in European sleep apnoea patients. *PlosOne* 2016; Oct 4;11(10):e0163439. (IF 3.240)
  38. Anttalainen U, Melkko S, Hakko S, Laitinen T, Saaresranta T. Telemonitoring of CPAP therapy may save nursing time. *Sleep Breath* 2016; 20:1209-15. (IF 2.816)
  39. Marrone O, Battaglia S, Steiropoulos P, Basoglu OK, Kvamme JA, Ryan S, Pepin JL, Verbraecken J, Grote L, Hedner J, Bonsignore MR; ESADA study group. Chronic kidney disease in European patients with obstructive sleep apnea: the ESADA cohort study. *J Sleep Res* 2016 May 18. doi: 10.1111/jsr.12426. (IF 3.981)
  40. Myllylä M, Kurki S, Anttalainen U, Saaresranta T, Laitinen T. High Adherence to CPAP Treatment Does Not Prevent the Continuation of Weight Gain among Severely Obese OSAS Patients. *J Clin Sleep Med* 2016; 12:519-28. (IF 4.062)

41. Escourrou P, Grote L, Penzel T, McNicholas WT, Verbraecken J, Tkacova R, Riha RL, Hedner J; ESADA Study Group. The diagnostic method has a strong influence on classification of obstructive sleep apnea. *J Sleep Res* 2015; 24:730-8. (IF 3.981)
42. Rimpilä V, Hosokawa K, Huhtala, H, Saaresranta T, Salminen AV, Polo O. Transcutaneous carbon dioxide during sleep-disordered breathing. *Respir Physiol Neurobiol* 2015; 219:95-102. (IF 1.931)
43. Nikolakaros G, Virtanen I, Markkula J, Saaresranta T. Obstructive sleep apnea in psychiatric outpatients. A clinic-based study. *J Psychiatr Res* 2015; 69:126-34. (IF 4.791)
44. Kent BD, Grote L, Ryan S, Pepin J-L, Bonsignore M, Tkacova R, Saaresranta T, Verbraecken J, Lévy P, Hedner J, McNicholas W. Diabetes mellitus prevalence and control in sleep disordered breathing: the European Sleep Apnea Cohort (ESADA) study. *Chest* 2014; 146:982-90. (IF 9.410)
45. Tkacova R, McNicholas WT, Javorsky M, Fietze I, Sliwinski P, Parati G, Grote L, Hedner J; European Sleep Apnoea Database study collaborators. Nocturnal intermittent hypoxia predicts prevalent hypertension in the European Sleep Apnoea Database cohort study. *Eur Respir J* 2014; 44:931-41. (IF 16.671)
46. Kent BD, Grote L, Bonsignore M, Saaresranta T, Verbraecken J, Levy P, Sliwinski P, Tkacova R, Kvamme J, Hedner J, McNicholas WT. Sleep apnoea severity independently predicts glycaemic health in non-diabetic subjects. *Eur Respir J* 2014; 44:130-9. (IF 16.671)
47. Lampio L, Polo-Kantola P, Polo O, Kauko T, Aittokallio J, Saaresranta T. Sleep in midlife women: the effect of menopause, depressive and vasomotor symptoms. *Menopause* 2014; 21:1217-24. (IF 2.953)
48. Gylén E, Anttalainen U, Saaresranta T. Relationship between habitual sleep duration, obesity and depressive symptoms in patients with sleep apnoea. *Obes Res Clin Pract* 2014; 8:e459-65 (IF 2.062)
49. Rimpilä V, Saaresranta T, Huhtala H, Virkki A, Salminen A, Polo O. Transcutaneous CO<sub>2</sub> plateau as set-point for respiratory drive during upper airway flow-limitation. *Respir Physiol Neurobiol* 2014; 191:44-51. (IF 1.931)
50. Anttalainen U, Saaresranta T, Vahlberg T, Polo O. Short-term medroxyprogesterone acetate in postmenopausal women with sleep-disordered breathing – a placebo-controlled, randomized, double-blind parallel group study. *Menopause* 2014; 21:361-8. (IF 2.953)
51. Karimi M, Hedner J, Lombardi C, McNicholas WT, Penzel T, Riha RL, Rodenstein D, Grote L; ESADA Study Group. Driving habits and risk factors for traffic accidents among sleep apnea patients--A European multi-centre cohort study. *J Sleep Res.* 2014 Dec;23(6):689-99. doi: 10.1111/jsr.12171. Epub 2014 Jul 7. (IF 3.981)
52. Siirala W, Aantaa R, Olkkola KT, Saaresranta T, Vuori A. Is the effect of non-invasive ventilation on survival in amyotrophic lateral sclerosis age-dependent? A retrospective cohort study. *BMC Palliat Care* 2013; 12:23. DOI: 10.1186/1472-684X-12-23 (IF 3.204)
53. Lampio L, Saaresranta T, Polo O, Polo-Kantola P. Subjective sleep in premenopausal and postmenopausal women on work and leisure days: a sleep diary study. *Menopause* 2013; 20:655-60. (IF 2.953)
54. Anttalainen U, Polo O, Vahlberg T, Saaresranta T. Women with partial upper airway obstruction are not less sleepy than those with obstructive sleep apnoea. *Sleep Breath* 2013; 17:873-6. (IF 2.816)
55. Siirala W, Saaresranta T, Vuori A, Salanterä S, Olkkola KT, Aantaa R. Using respiratory rate and thoracic movement to assess respiratory insufficiency in amyotrophic lateral sclerosis: a preliminary study. *BMC Palliat Care* 2012 Dec 27;11:26. doi:10.1186/1472-684X-11-26. (IF 3.204)
56. Hedner J, Grote L, Bonsignore M, McNicholas W, Lavie P, Parati G, Sliwinski P, Barbé F, Escourrou P, Fietze I, Masa JFM, Kvamme JA, Lombardi C, Marrone O, Monserrat JM, Penzel T, Pretl M, Riha R, Rodenstein D, Saaresranta T, Schultz R, Tkacova R, Varoneckas G, Vitols A,

- Vrints H., Zielinski J, Debacker W. The European Sleep Apnea Database (ESADA) – report from 22 European sleep laboratories. *Eur Respir J* 2011; 38:635-42. (IF 16.671)
57. Fietze I, Penzel T, Alonderis A, Barbe F, Donic V, Franklin KA, Jennum P, Gislason T, Hedner J, Lavie P, Marrone O, Montserrat JM, Papathanasiou ES, Parati G, Plywaczewski R, Pretl M, Riha RL, Rodenstein D, Saaresranta T, Schultz R, Svaza J, Tomori Z, Varoneckas G, Verbraecken J, McNicholas WT; COST Action B26 Group. Management of obstructive sleep apnea in Europe. *Sleep Med* 2011; 12:190-7. (IF 3.492)
  58. Anttalainen U, Liippo K, Saaresranta T. Diagnosis and initiation of nasal continuous positive airway pressure therapy for OSAS without a preceding sleep study? *Sleep Breath* 2011; 15:791-7. (IF 2.816)
  59. Anttalainen U, Polo O, Vahlberg T, Saaresranta T. Reimbursed drugs in patients with sleep-disordered breathing - a static-charge-sensitive bed study. *Sleep Med* 2010; 11:49-55. (IF 3.492)
  60. Korhonen P, Vesalainen R, Aarnio P, Saaresranta T, Kautiainen H, Järvenpää S, Kantola I. The assessment of total cardiovascular risk in hypertensive subjects in primary care. *Ann Med* 2010; 42: 187-95. (IF 4.709)
  61. Aittokallio J, Saaresranta T, Virkki A, Karppinen N, Heinonen O, Aittokallio T, Polo O. Transcutaneous carbon dioxide profile during sleep reveals metabolic risk factors in postmenopausal women. *Eur Respir J* 2009; 34:1132-9 (IF 16.671)
  62. Aittokallio J, Hiissa J, Saaresranta T, Polo-Kantola P, Aittokallio T, Polo O. Nocturnal transcutaneous carbon dioxide tension in postmenopausal estrogen-users and non-users. *Menopause International* 2009; 15:107-12
  63. Sjösten N, Vahtera J, Salo P, Oksanen T, Saaresranta T, Virtanen M, Pentti J, Kivimäki N. Increased risk of lost work days prior to the diagnosis of sleep apnea. *Chest* 2009; 136:130-6. (IF 9.410)
  64. Sjösten N, Kivimäki N, Oksanen T, Salo P, Saaresranta T, Virtanen M, Pentti J, Vahtera J. Obstructive sleep apnea syndrome as a predictor of work disability. *Respir Med* 2009; 103: 1047 – 55. (IF 3.415)
  65. Korhonen P, Aarnio P, Vesalainen R, Saaresranta T, Kautiainen H, Järvenpää S, Kantola I. Hypertensive women with the metabolic syndrome are at risk of renal insufficiency more than men in general population. *J Human Hypertens* 2009; 23: 97-104. (IF 3.012)
  66. Korhonen PE, Jaatinen PT, Aarnio PT, Kantola IM, Saaresranta T. Waist circumference home measurement – a device to find out patients in cardiovascular risk. *Eur J Public Health* 2009; 19: 95-9. (IF 3.367)
  67. Aittokallio J, Polo O, Hiissa J, Virkki A, Toikka J, Raitakari O, Saaresranta T, Aittokallio T. Overnight variability in transcutaneous carbon dioxide predicts vascular impairment in women. *Exp Physiol* 2008; 93: 812-823. (IF 2.969)
  68. Saaresranta T, Anttalainen U, Toikka J, Polo O. Dyspnoea: diagnostic challenge. *Breathe* 2008; 4: 269-273.
  69. Korhonen P, Aarnio P, Saaresranta T, Jaatinen P, Kantola I. Glucose homeostasis in hypertensive subjects. *Hypertension* 2008; 51: 1-5. (IF 10.190)
  70. Virkki A, Polo O, Saaresranta T, Laapotti-Salo A, Gyllenberg M, Aittokallio T. Overnight features of transcutaneous carbon dioxide measurement as predictors of metabolic status. *Artif Intell Med* 2008; 42:55-65. (IF 5.326)
  71. Alonderis A, Barbé F, Bonsignore M, Calverley P, De Backer W, Diefenbach K, Donic V, Fanfulla F, Fietze I, Franklin K, Grote L, Hedner J, Jennum P, Krieger J, Levy P, McNicholas W, Montserrat J, Parati G, Pascu M, Penzel T, Riha R, Rodenstein D, Sanna A, Schulz R, Sforza E, Sliwinski P, Tomori Z, Tonnesen P, Varoneckas G, Zielinski J, Kostelidou K; COST Action B-26 Collaborators Valmain J, Vaa T, Trakadas A, Lauer R, Buhagiar G, Lehotska A, Vitenas M, Dolenc L, Iversen J, Knapskog AB, Brady N, Hollenstein T, Aad G, Saaresranta T, Hochmann M, Staus G, Zuidema C, Bittner M, Topelius M, Raimondo I, Pindmaa M, Erzsébet K, Wijkstra

- P, Tomori Z. Medico-legal implications of sleep apnoea syndrome: driving license regulations in Europe. *Sleep Med* 2008; 9:362-75. (IF 3.492)
72. Anttalainen U, Saaresranta T, Kalleinen N, Aittokallio J, Vahlberg T, Polo O. Gender differences in age and BMI distributions in partial upper airway obstruction during sleep. *Respir Physiol Neurobiol* 2007; 159: 219-226. (IF 1.931)
73. Anttalainen U, Saaresranta T, Kalleinen N, Aittokallio J, Vahlberg T, Polo O. CPAP adherence and partial upper airway obstruction during sleep. *Sleep Breath* 2007; 11:171-176. (IF 2.816)
74. Anttalainen U, Saaresranta T, Aittokallio J, Kalleinen N, Vahlberg T, Virtanen I, Polo O. Impact of menopause on the manifestation and severity of sleep-disordered breathing. *Acta Obstet Gynecol Scand* 2006; 85(11):1381-8. (IF 3.636)
75. Saaresranta T, Polo-Kantola P, Virtanen I, Vahlberg T, Irjala K, Polo O. Menopausal estrogen therapy predicts better nocturnal oxyhemoglobin saturation. *Maturitas* 2006; 55:255-263. (IF 4.342)
76. Aittokallio J, Virkki A, Aittokallio T, Saaresranta T, Polo-Kantola P, Polo O. Non-invasive respiratory monitoring during wakefulness and sleep in pre- and postmenopausal women. *Respir Physiol Neurobiol* 2006; 150: 66-74. (IF 1.931)
77. Saaresranta T, Aittokallio T, Utriainen K, Polo O. Medroxyprogesterone improves nocturnal breathing in postmenopausal women with chronic obstructive pulmonary disease. *Respir Research* 2005, Apr 4; 6 (1):28 (12 s.) <http://respiratory-research.com/content/6/1/28>. (IF 5.631)
78. Saaresranta T, Aittokallio T, Irjala K, Polo O. Sleep quality, daytime sleepiness and fasting insulin levels in women with chronic obstructive pulmonary disease. *Respir Med* 2005; 99: 856-863. (IF 3.415)
79. Virtanen I, Polo O, Saaresranta T, Kuusela T, Polo-Kantola P, Ekholm E. MPA improves cardiac autonomic control in postmenopausal women with respiratory insufficiency. *Respir Med* 2004; 98:126-33. (IF 3.415)
80. Saaresranta T, Polo O. Long-term progestin therapy for female chronic respiratory insufficiency? *Respir Med* 2004; 98:194-5. (IF 3.415)
81. Aittokallio T, Gyllenberg M, Saaresranta T, Polo O. Prediction of inspiratory flow shapes during sleep with a mathematical model of upper airway forces. *Sleep* 2003; 29:857-63. (IF 5.849)
82. Saaresranta T, Aittokallio T, Polo-Kantola P, Helenius H, Polo O. Effect of medroxyprogesterone on inspiratory flow shapes during sleep in postmenopausal women. *Respir Physiol Neurobiol* 2003; 134:131-43. (IF 1.931)
83. Saaresranta T, Irjala K, Polo O. Effect of medroxyprogesterone acetate on arterial blood gases, serum leptin and neuropeptide Y in postmenopausal females. *Eur Respir J* 2002; 20:1413-8. (IF 16.671)
84. Saaresranta T, Uotila P, Saraste M, Irjala K, Hartiala J, Polo O. Effect of medroxyprogesterone on pulmonary arterial pressure, exhaled nitric oxide, ECG, and arterial blood gases. *J Intern Med* 2002; 251: 421-8. (IF 8.989)
85. Saaresranta T, Irjala K, Polo-Kantola P, Polo O. Medroxyprogesterone-induced endocrine alterations after menopause. *Menopause* 2002; 9:288-91. (IF 2.953)
86. Saaresranta T, Polo-Kantola P, Rauhala E, Polo O. Medroxyprogesterone in postmenopausal females with partial upper airway obstruction during sleep. *Eur Respir J* 2001; 18:989-95. (IF 16.671)
87. Polo-Kantola P, Rauhala E, Saaresranta T, Aittokallio T, Erkkola R, Polo O. Climacteric vasomotor symptoms do not predict nocturnal breathing abnormalities in postmenopausal women. *Maturitas* 2001; 39:29-37. (IF 4.342)
88. Aittokallio T, Saaresranta T, Polo-Kantola P, Nevalainen O, Polo O. Analysis of inspiratory flow shapes in patients with partial upper airway obstruction during sleep. *Chest* 2001; 119:37-44. (IF 9.410)

89. Saaresranta T, Irjala K, Polo-Kantola P, Helenius H, Polo O. Prolonged endocrine responses to medroxyprogesterone in postmenopausal women with respiratory insufficiency. *Obstet Gynecol* 2000; 96:243-9. (IF 7.661)
90. Saaresranta T, Irjala K, Polo-Kantola P, Helenius H, Polo O. IGF-I and ventilation after short-term progestin in postmenopausal women with chronic respiratory insufficiency. *Respir Med* 2000; 94:909-16. (IF 3.415)
91. Saaresranta T, Polo-Kantola P, Irjala K, Helenius H, Polo O. Respiratory insufficiency in postmenopausal women: sustained improvement with short-term medroxyprogesterone acetate. *Chest* 1999; 115:1581-587. (IF 9.410)
92. Aittokallio T, Nevalainen O, Pursiheimo U, Saaresranta T, Polo O. Classification of nasal inspiratory flow shapes by attributed finite automata. *Comput Biomed Res* 1999; 32:34-55. (IF 6.317)
93. Salomaa E-R, Viander M, Saaresranta T, Terho E O. Complement components and their activation products in pleural fluid. *Chest* 1998;114:723-30. (IF 9.410)
94. Saaresranta T, Terho E O. Nizatidine inhibits reactions in skin-prick tests. *Clin Exp Allergy* 1995; 25:574. (letter) (IF 5.018)

## 2) Review articles in international peer-reviewed journals

95. Almendros I, Basoglu ÖK, Conde SV, Liguori C, Saaresranta T. Metabolic dysfunction in OSA: Is there something new under the sun? *J Sleep Res* 2021; accepted for publication (IF 3.981)
96. Bonsignore MR, Saaresranta T, Riha R. Sex differences in obstructive sleep apnoea. *Eur Respir Rev* 2019; Nov 6;28(154). DOI: 10.1183/16000617.0030-2019 (IF 8.839)
97. Bonsignore MR, Hedner J; ESADA study group. The European Sleep Apnoea Database (ESADA) ERS Clinical Research Collaboration: past, present and future. *Eur Respir J*. 2018 Oct 10;52(4): 1801666. doi: 10.1183/13993003.01666-2018. Print 2018 Oct. (IF 16.671)
98. Anttalainen U, Tenhunen M, Rimpilä V, Polo O, Rauhala E, Himanen S-L, Saaresranta T. Prolonged partial upper airway obstruction during sleep – an underdiagnosed phenotype of sleep-disordered breathing. *Eur Clin Respir J* 2016; 3: 31806 - <http://dx.doi.org/10.3402/ecrj.v3.31806>
99. Saaresranta T, Anttalainen U, Polo O. Sleep disordered breathing – different for females? *ERJ Open Res* 2015; 1: 00063-2015; DOI: 10.1183/23120541.00063-2015 (Editorial)
100. Parati G, Lombardi C, Hedner J, Bonsignore MR, Grote L, Tkacova R, Levy P, Riha R, Bassetti C, Narkiewicz K, Mancina G, McNicholas WT; on behalf of the EU COST ACTION B26 members. ERS/ESH Task Force Report. Recommendations for the management of patients with obstructive sleep apnoea and hypertension. *Eur Respir J* 2013; 41:523-68. (IF 16.671)
101. Parati G, Lombardi C, Hedner J, Bonsignore MR, Grote L, Tkacova R, Levy P, Riha R, Bassetti C, Narkiewicz K, Mancina G, McNicholas WT; European Respiratory Society; EU COST ACTION B26 members. Position paper on the management of patients with obstructive sleep apnea and hypertension; joint recommendations of by the European Society of Hypertension, by the European Respiratory Society and by the members of European COST (COoperation in Scientific and Technological research) ACTION B26 on obstructive sleep apnea. *J Hypertens* 2012; 30:633-46. (IF 4.844)
102. Anttalainen U, Polo O, Saaresranta T. Is "mild" sleep-disordered breathing in women really mild? *Acta Obstet Gynecol Scand* 2010; 89: 605-11. (IF 3.636)
103. Saaresranta T, Polo O. Does leptin link sleep loss and breathing disturbances with major public diseases? *Ann Med* 2004; 36:172-83. (IF 4.709)
104. Saaresranta T, Polo O. Sleep-disordered breathing and hormones. *Eur Respir J* 2003; 22:161–72. (IF 16.671)
105. Saaresranta T, Polo O. Hormones and breathing. *Chest* 2002; 122:2165-82. (IF 9.410)

106. Polo-Kantola P, Saaresranta T, Polo O. Aetiology and treatment of sleep disturbances during menopause. *CNS Drugs* 2001; 15: 445– 52. (IF 5.749)

### 3) Original articles in Finnish peer-reviewed journals

107. Salomaa E-R, Myllylä M, Kurki S, Anttalainen U, Virkkala J, Saaresranta T, Laitinen T. Uniapneapotilas 2000-luvulla: kenelle CPAP-hoito aloitetaan ja miten siihen sitoudutaan? [Commencement of and adherence to CPAP treatment of patients with sleep-disordered breathing]. *Duodecim* 2013; 129(20):2175-2182.
108. Ahonen S, Anttalainen U, Saaresranta T, Grénman R. Reinken ödeeman ja äänihuulihalvauksen aiheuttaman hengenahdistuksen oireenmukainen hoito itsesäätyvällä CPAP-laitteella. [Symptomatic treatment with a self-adjusting CPAP device of dyspnea caused by Reinke's edema and vocal cord paralysis] *Duodecim* 2013;129(16):1718-1721.
109. Heino M, Leinonen M, Saaresranta T. Yhtenäisten kiirettömän hoidon perusteiden vaikutus keuhkosairauksien läheteisiin. [Effect of national guidelines for the quality of referrals to the pulmonary clinics.] *Suomen Lääkärilehti* 2010; 65(23): 2106 – 2110.
110. Virtanen I, Junnila SYT, Saaresranta T. Yöpolygrafia normaali – ei unenaikaista hengityshäiriötä? [Normal cardiorespiratory polygraphy – no sleep-disordered breathing?] *Suomen Lääkärilehti* 2009; 64(40):3325 – 3328.
111. Saaresranta T. Hengenahdistusta tiskatessa. [Dyspnoea as the first sign of latex allergy] *Duodecim* 1996; 112(18):1657-1658.
112. Saaresranta T, Söderström K-O, Ruokonen E-L. Kylothorax ja kyloaskites Castlemanin taudin oireena. [Chylothorax and chylous ascites as symptoms of Castleman's disease] *Duodecim* 1995; 111(4):348 - 350.

### 4) Review articles in Finnish peer-reviewed journals

113. Saaresranta T. Uniapnean hoidonporrastus ulottuu monelle tasolle. [Integrated health care on different levels of health care system.] *Lääkärilehti* 2021; 76:884 – 6.
114. Lyyra O, Lammintausta A, Anttalainen U, Saaresranta T. Ikääntyminen ja uniapnea. [Ageing and sleep apnoea.] *Duodecim* 2021; accepted for publication
115. Kroneld L, Polo P, Saaresranta T, Anttalainen U, Jokimaa V. Munasarjojen monirakkulaoireyhtymä ja unihäiriöt. [Polycystic ovary syndrome and sleep disorders.] *Duodecim* 2020; 137(13):1391-8.
116. Aro M, Myllylä M, Anttalainen U, Saaresranta T. Näin tutkin: uniapneaepäily. [Investigations with suspected sleep apnoea] *Duodecim* 2019; 135(17):1627-1635.
117. Saaresranta T, Anttalainen U, Elenius V, Himanen S-L, Lamusuo S, Markkula J, Saarenpää-Heikkilä O, Siirala W, Soukka T. Uni- ja hengityskeskus yhtenäistää diagnostiikkaa ja hoitoa. [Sleep and breathing centre is harmonizing diagnostics and treatment.] *Suomen Lääkärilehti* 2019; 74(15-16):965-967.
118. Lampio L, Saaresranta T, Polo P. Unettomuusoireet vaihdevuosien aikana. [Symptoms of insomnia during menopause] *Duodecim* 2018; 134(6):555-562.
119. Saaresranta T, Anttalainen U. Uniapnean ja hengitysvajeen etähoito ei ole enää etäällä. [Telecare of sleep apnoea and respiratory insufficiency is not any more far away.] Editorial. *Suomen Lääkärilehti* 2017; 72(37):1985.
120. Saaresranta T, Anttalainen U, Fagerudd S, Myllylä M, Polo O, Simonds A, Vuori A, Laitinen T. Hengitystukihoitojen auditointi lisäsi luottamusta omaan tekemiseen Turussa.

- [Audit of respiratory support treatment increased confidence for SOPs.] *Suomen Lääkärilehti* 2016; 71(3):168-169.
121. Siirala W, Korpela J, Vuori A, Saaresranta T, Olkkola K, Aantaa R. Amyotrofinen lateraaliskleroosi ja hengitysvajaus. [Amyotrophic lateral sclerosis and respiratory insufficiency] *Duodecim*. 2015;131(2):127-135.
  122. Saaresranta T, Anttalainen U, Brander P, Lojander J, Polo O. Uniapneapotilaiden CPAP-hoidon seuranta siirtyy yhä useammin perusterveydenhuoltoon. [Increasing follow-up of obstructive sleep apnoea patients in primary care] *Suomen Lääkärilehti* 2012; 67(42):3001-3005.
  123. Himanen S-L, Rauhala E, Saaresranta T. Kansantauti uniapnea – pitäisikö seuloa? [Sleep apnoea as a national disease, should we screen for it?] *Suomen Lääkärilehti* 2012; 67(34):2293-2297.
  124. Saaresranta T, Anttalainen U, Polo O. Kaksoispaineventilaatio kroonisessa hengitysvajauksessa. Näin hoidan. [Possibilities of bi-level positive pressure ventilation in chronic hypoventilation]. *Duodecim* 2011; 127(17):1797-807.
  125. Saaresranta T, Anttalainen U, Brander P, Helin-Salmivaara A, Hiltunen L, Himanen Sari-Leena, Lojander J, Pakkala R, Partinen M, Polo O, Seppä J. Käypä hoito. Aikuisten obstruktiivinen uniapnea. [Update on current care guidelines: obstructive sleep apnoea syndrome in adults]. *Duodecim* 2010; 126(22):2633-2635.
  126. Saaresranta T. Unilääketieteen erityispätevyys. [Special competence of sleep medicine.] *Suomen Lääkärilehti* 2005; 60(34):3299-3301

## 5) International textbooks and chapters

127. Porkka-Heiskanen T, Saaresranta T, Polo-Kantola P. Gender differences in sleep. pp. 109 -122. In: Bassetti C, McNichola W, Paunio T, Peigneux P (eds.). *Sleep Medicine Textbook*. 2nd ed. 1100 pages. ISBN: 9781119789017. European Sleep Research Society (ESRS), Regensburg, Germany, 2021.
128. Polo-Kantola P, Saaresranta T, Lampio L. Sleep and sleep disturbances in climacteric women, p. 261-281 In: Pérez-López FR. (eds). *Postmenopausal diseases and disorders*. DOI 10.1007/978-3-030-13936-0\_17. Print ISBN 978-3-030-13935-3, online ISBN 978-3-030-13936-0; <https://doi.org/10.1007/978-3-030-13936-0>, Springer Nature Switzerland, 2019
129. Porkka-Heiskanen T, Saaresranta T, Polo-Kantola P. Gender differences in sleep, p. 83-94. In: Bassetti C, Dogas Z, Peigneux P (eds.). *Sleep Medicine Textbook*. 1. edition, 527 s. European Sleep Research Society (ESRS), 2014 ISBN: 9781119038931.
130. Saaresranta T, Polo-Kantola P, Polo O. Practical approach to the diagnosis and management of menopausal insomnia, p. 293 - 324. In: Attarian H, Viola-Saltzman M (eds.). *Sleep Disorders in Women: A Guide to Practical Management*. 2. edition, 348 s. Humana press/Springer, The Netherlands, 2013. ISBN: 978-1-62703-323-7 (Print) 978-1-62703-324-4 (Online)
131. Saaresranta T. Obstructive sleep apnea in adults, p. 79 – 87. In: Lindgren K-A (ed.). *Sleep, Pain and Wellbeing*. 12th Physiatric Summer School 18. - 19.8.2011 Helsinki. Orton Foundation. Vammalan kirjapaino 2012.
132. Saaresranta T, Polo-Kantola P, Polo O. Menopausal insomnia, p. 117 – 136. In: Attarian H, Schuman C (eds.). *Clinical Handbook of Insomnia*. 2<sup>nd</sup> ed. 362 p. Springer: Humana Press, USA, 2010.

133. Saaresranta T. Female hormones and sleep-disordered breathing, p. 17 - 23. In: Kumar VM, Mallick HN (eds). *Proceedings of the 2nd Interim Congress of the World Federation of Sleep Research and Sleep Medicine Societies - WFSRSMS*. Medimond, Bologna, Italia, 2005
134. Saaresranta T, Polo O. Sleep-disordered breathing and hormones, p. 437-470. In: Cardinali D and Pandi-Perumal SR (eds.). *Neuroendocrine correlates of sleep/wakefulness*. 1<sup>st</sup> ed. Springer, New York, USA, 2005.

## 6) Finnish textbooks and chapters

135. Saaresranta T. Kuorsaus ja hengityskatkokset. [Snoring and witnessed apnoeas.] pp. 107-8, In: Kaarteenaho R, Halme M, Koskela H, Saaresranta T (eds.). *Keuhkosairaudet – diagnostiikka ja hoito. [Respiratory diseases – diagnostics and treatment.]* 533 pages. 2<sup>nd</sup> edition. Print ISBN 978-951-656-991-1. Kustannus Oy Duodecim 2021.
136. Saaresranta T, Brander P. Krooninen hengitysvajaus. [Chronic respiratory failure.] pp. 365-82. In: Kaarteenaho R, Halme M, Koskela H, Saaresranta T (eds.). *Keuhkosairaudet – diagnostiikka ja hoito. [Respiratory diseases – diagnostics and treatment.]* 533 pages. 2<sup>nd</sup> edition. Print ISBN 978-951-656-991-1. Kustannus Oy Duodecim 2021.
137. Saaresranta T, Polo O. Uniapnea. [Sleep apnoea.] pp. 384 – 412. In: Kaarteenaho R, Halme M, Koskela H, Saaresranta T (eds.). *Keuhkosairaudet – diagnostiikka ja hoito. [Respiratory diseases – diagnostics and treatment.]* 533 pages. 2<sup>nd</sup> edition. Print ISBN 978-951-656-991-1. Kustannus Oy Duodecim 2021.
138. Brander P, Saaresranta T. Kuorsaus ja hengityskatkokset. [Snoring and witnessed apnoeas.] Pp. 102 – 103. In: Kaarteenaho R, Brander P, Halme M, Kinnula V (eds.). *Keuhkosairaudet – diagnostiikka ja hoito. [Respiratory diseases – diagnostics and treatment.]* Kustannus Oy Duodecim, 2013
139. Saaresranta T, Brander P. Krooninen hengitysvajaus. [Chronic respiratory failure.] Pp. 340 – 355. In: Kaarteenaho R, Brander P, Halme M, Kinnula V (eds.). *Keuhkosairaudet – diagnostiikka ja hoito. [Respiratory diseases – diagnostics and treatment.]* Kustannus Oy Duodecim, 2013
140. Saaresranta T, Polo O. Uniapnea. [Sleep apnoea.] Pp. 356 – 381. In: Kaarteenaho R, Brander P, Halme M, Kinnula V (eds.). *Keuhkosairaudet – diagnostiikka ja hoito. [Respiratory diseases – diagnostics and treatment.]* Kustannus Oy Duodecim, 2013
141. Saaresranta T, Paljakka K. Hengityselinsairaudet ja hengitysvaje. [Respiratory diseases and respiratory failure.] Pp. 368 – 386. In: Arokoski J, Alaranta H, Pohjolainen T, Salminen J, Viikari-Juntura E (eds.). *Fysiatria. [Physiatry.]* 4. ed. Kustannus Oy Duodecim, Keuruu, 2009.
142. Saaresranta T, Polo O. Krooninen hengitysvajaus. [Chronic respiratory failure.] Pp. 664 - 83. In: Kinnula V, Brander P, Tukiainen P (eds.). *Keuhkosairaudet. [Respiratory diseases]* 3. ed. Kustannus Oy Duodecim, Hämeenlinna, 2005.
143. Polo O, Kirjavainen T, Saaresranta T. Cheyne-Stokes-hengitys ja sentraaliset hengityshäiriöt. [Cheyne-Stokes respiration and central hypoventilation syndromes.] Pp. 705 – 11. In: Kinnula V, Brander P, Tukiainen P (eds.). *Keuhkosairaudet. [Respiratory diseases]* 3. ed. Kustannus Oy Duodecim, Hämeenlinna, 2005.

## 7) Other publications

144. Saaresranta T ja Anttalainen U: Traficom ajoterveyden arviointiohjeiden soveltaminen uniapneapotilaiden ajoterveyden arvioinnissa. *Erikoislääkäri* 2/2021;31 vsk;A63-A66

145. Anttalainen U, Saaresranta T, Hasala H. CPAP-hoidon seuranta pitkäaikaishoidossa. [Follow-up of longterm CPAP treatment.] In: Jäppinen M, Karjalainen M, Metsävainio H (eds.) Hengityksen tuki- ja korvaushoidon laitteet. [Devices for respiratory support.] Kustannusosakeyhtiö Duodecim, Oppiportti 2020
146. Anttalainen U, Saaresranta T. CPAP-laitteen käytön ongelmatilanteet pitkäaikaishoidossa. [Problems in long-term CPAP treatment.] In: Jäppinen M, Karjalainen M, Metsävainio H (eds.) Hengityksen tuki- ja korvaushoidon laitteet. [Devices for respiratory support.] Kustannusosakeyhtiö Duodecim, Oppiportti 2020
147. Anttalainen U, Saaresranta T, Aalto S, Rantala H, Hasala H. Kaksoispaineventilaatiohoidon seuranta pitkäaikaishoidossa. [Follow-up of long-term bilevel ventilation.] In: Jäppinen M, Karjalainen M, Metsävainio H (eds.) Hengityksen tuki- ja korvaushoidon laitteet. [Devices for respiratory support.] Kustannusosakeyhtiö Duodecim, Oppiportti 2020
148. Anttalainen U, Saaresranta T, Aalto S. Kaksoispaineventilaatiolaitteen käytön ongelmatilanteet pitkäaikaishoidossa. [Solving problems in long-term bilevel ventilation.] In: Jäppinen M, Karjalainen M, Metsävainio H (eds.) Hengityksen tuki- ja korvaushoidon laitteet. [Devices for respiratory support.] Kustannusosakeyhtiö Duodecim, Oppiportti 2020
149. Aalto S, Anttalainen U, Saaresranta T. Kaksoispaineventilaatiolaitteen säätäminen pitkäaikaishoidossa. [Settings of bilevel ventilator in long-term treatment.] In: Jäppinen M, Karjalainen M, Metsävainio H (eds.) Hengityksen tuki- ja korvaushoidon laitteet. [Devices for respiratory support.] Kustannusosakeyhtiö Duodecim, Oppiportti 2020
150. Korhonen P, Saaresranta T. Obstruktiivinen uniapnea.[Obstructive sleep apnoea] *Yleislääkäri* 2018; 33(2): 9 – 12.
151. Nurmi S, Saaresranta T, Koivisto T, Meriheinä U, Palva L. Validation of an accelerometer based BCG method for sleep analysis. Aalto University publication series SCIENCE + TECHNOLOGY, 7/2016, ISBN 978-952-60-6842-8 (electronic), ISSN 1799-490X (electronic), 1799-4896 (ISSN-L).
152. Saaresranta T. Diabetes ja verensokeritasapaino ESADA-kohortin uniapneapotilailla.[Diabetes and glucose balance in sleep apnoea patients of the ESADA cohort.] *Allergiakoulu*; Allergiatutkimussäätiön 43. vuosikirja 2015; 43:74-75. Newprint Oy, Raisio, 2015.
153. Saaresranta T, Anttalainen U. Riittämätön uni on vakava terveystarve. [Insufficient sleep is a serious health risk.] *Alio Turun Sanomat* 9.4.2015
154. Saaresranta T, Vuori A. Mitä anestesiahoitajan tulisi tietää noninvasiivisesta ventilaatiosta? [What should anesthesiologist know about noninvasive ventilation?] *Spirium* 2014; 49(4):14-17.
155. Polo P, Saaresranta T. Naisen uni vaihdevuosien aikana. [Sleep in menopausal women.] *Erikoislääkärilehti* 2014;14(4):119-123.
156. Saaresranta T. Hyvän unen salaisuus. [The secret of good sleep.] *UTUonline* 22.3.2012 [http://www.tuonline.fi/sisalto/artikkeli/Hyvan\\_unen\\_salaisuus.html](http://www.tuonline.fi/sisalto/artikkeli/Hyvan_unen_salaisuus.html)
157. Saaresranta T. Uutta uniapneasta. [What's new in sleep apnoea?] *Hengitys* 2012;1:12-13.
158. Kalleinen N, Anttalainen U, Saaresranta T. Hyviä kokemuksia ASV-hoidosta TYKS:ssä. [Good experience from ASV treatment in the Turku University Hospital.] *Suomen Lääkärilehti* 2011;66:3512-3513
159. Vuori A, Siirala W, Saaresranta T, Anttalainen U. Hengenahdistuksen palliativisesta hoidosta. [Palliative treatment of dyspnoea] *Suomen Lääkärilehti* 2011;66:1559.
160. Saaresranta T. Kannattaako obstruktiivista uniapneaa hoitaa? [Should we treat obstructive sleep apnoea?] *Erikoislääkäri* 2011; 21 (2):62 – 65.

161. Saaresranta T. ESADA - eurooppalainen uniapneakohortti. [ESADA – the European sleep apnoea cohort.] Allergiakoulu; Allergiatutkimussäätiön vuosikirja 2010:38:54-55. Newprint Oy, Loimaa, 2010.
162. Saaresranta T. Yöllinen transkutaaninen hiilidioksidin mittausta metabolisen tilan peilinä. [Nocturnal transcutaneous measurement of carbon dioxide level mirrors metabolism.] Allergiakoulu 2009; Allergiatutkimussäätiön 37. vuosikirja, p. 83. Newprint Oy, Loimaa, 2009.
163. Saaresranta T. ESADA – eurooppalainen maailman suurin uniapneapotilaiden tietokanta. [ESADA – the European and world’s largest sleep apnoea database.] Allergiakoulu 2008; Allergiatutkimussäätiön 36. vuosikirja, pp. 96 – 97. Newprint Oy, Loimaa, 2008.
164. Korhonen P, Aarnio P, Saaresranta T., Jaatinen P, Kantola I. Glukoositasapainon häiriöt yleisiä verenpainepotilailla. [Disturbances in glucose balance are common in hypertensive patients.] Duodecim 2008; 124:723.
165. Saaresranta T., Anttalainen U, Äyräs O. Uniapnean hoito kannattaa. [It is worth of treating sleep apnoea.] Vuosikatsaus 2007. Varsinais-Suomen sairaanhoitopiirin julkaisuja, sarja D, nro 21, 2008, ISSN 1796-1343.
166. Saaresranta T., Polo-Kantola P. Vaihdevuosi-ikäisen naisen uni ja unenaikaiset hengityshäiriöt. [Sleep and sleep-disordered breathing in postmenopausal women.] Työterveyslääkäri 2007; n:o 3: 70 -76
167. Saaresranta T. Unenaikaiset hengityshäiriöt – naisten alidiagnosoitu kansantauti. [Sleep-disordered breathing – underdiagnosed major public disorder in women.] Hyvä Hengitys 2007; Lääkäriliite n:o 3: 1 – 3.
168. Saaresranta T. Keuhkohtaumataudin muu kuin lääkehoito. [Other treatment modes than medication for COPD.] Hengitysviesti 2006; n:o1: 4 - 5.
169. Saaresranta T. Unihäiriöt ja metabolinen oireyhtymä. [Sleep disorders and metabolic syndrome.] Diabetes ja Lääkäri 2006; 35 (1): 6 – 17.
170. Saaresranta T. Keuhkohtaumataudin lääkehoito. [Medication for COPD.] Tietoa Terveydestä 2005; s. 26.
171. Saaresranta T. Keuhkohtaumatauti: progestiinihoito, uni, päivävireys ja insuliiniresistenssi. [COPD: progestin therapy, sleep, vigilance and insulin resistance.] Haahtela T (toim): Allergiakoulu 2005; Allergiatutkimussäätiö, vuosikirja 33:86 - 87. Priimus Paino Oy, Loimaa 2005.
172. Saaresranta T. Unenaegsed hingamishäired ja hormoonid. (Unenaikaiset hengityshäiriöt ja hormonit). [Sleep-disordered breathing and hormones. In Estonian language] Ajakiri Eesti Arst 2005; 84(7):488-96.
173. Saaresranta T., Polo O. Sleep-disordered breathing in women. European Respiratory Society, Educational Website [www.ersnet.org](http://www.ersnet.org), accessible Dec 24, 2003.
174. Saaresranta T. Uniapnea – harvinaisuudesta kansantaudiksi myös naisilla. [Sleep apnoea – from rarity to a major public disease also in women.] Hengitysviesti 2003; n:o 4: 4–5.
175. Saaresranta T. Progestiini hengitysstimulanttina. [Progestin as a respiratory stimulant.] Haahtela T (toim): Allergiakoulu 2002; Allergiatutkimussäätiö, vuosikirja 30. Priimus Paino Oy, Loimaa 2002.
176. Saaresranta T. Progestiini ja unenaikainen osittainen ylähengitystieahtauma. [Progestin and partial upper airway obstruction during sleep.] Hyvä Hengitys 2001; Lääkäriliite 1:8–9.
177. Saaresranta T. Progestiinia keuhkohtaumatautiin. [Progestin therapy for COPD.] Hyvä Hengitys 2001; Lääkäriliite 2: 16-17.

178. Saaresranta T. Effect of medroxyprogesterone acetate on breathing and sleep in postmenopausal women with chronic respiratory failure or partial upper airway obstruction during sleep. Academic dissertation. Annales Universitatis Turkuensis D 422. 229 p. Painosalama Oy, Turku, 2000. ISBN 951-29-1814-5